Skip to main content

HLRCC Foundation

Contact & Join

What “FH-Deficient” on a Pathology Report Means — and What It Does Not

If a pathology report says a tumor is “FH-deficient,” or mentions staining for fumarate hydratase or something called 2SC, it is reasonable to wonder whether that means you have hereditary leiomyomatosis and renal cell cancer (HLRCC).

In short: those words describe what the tumor looks like under the microscope and with special stains. They are an important clue. They are not, by themselves, a diagnosis of HLRCC.

A quick refresher

HLRCC is caused by a harmful (pathogenic) variant in the FH gene, which makes an enzyme called fumarate hydratase. People with HLRCC can develop benign smooth-muscle growths in the skin and uterus (leiomyomas, including fibroids), and they have a higher risk of a type of kidney cancer. A 2014 expert consensus estimated kidney cancer risk at approximately 15 in 100 (about 15%), which means most people with HLRCC do not get kidney cancer. GeneReviews, the expert review hosted on NIH’s NCBI Bookshelf, is the main source for the points below. The National Cancer Institute’s HLRCC summary also notes the availability of stains that identify loss of FH and the presence of 2SC in tissue.

What “FH-deficient” is trying to say

Pathologists can stain tumor tissue to see whether the FH enzyme is present and whether a related chemical mark has built up.

According to GeneReviews:

  • FH-related kidney cancers often show loss of FH staining and positive staining for S-(2-succino) cysteine, often abbreviated 2SC (some labs write 2-SC).
  • Uterine fibroids in this condition tend to be numerous and large, and they often show the same pattern: loss of FH staining and positive 2SC staining.

In plain language, the tumor cells look as if they have lost a working FH enzyme, and a byproduct of that loss (2SC) is showing up in the tissue. That pattern is why a report may say “FH-deficient.”

What it does not mean by itself

An FH-deficient tumor is not the same thing as a diagnosis of HLRCC. GeneReviews is clear that the diagnosis of FH tumor predisposition syndrome (the formal name it uses for HLRCC) is established in a person who has a heterozygous pathogenic or likely pathogenic variant in FH identified by molecular genetic testing. A variant of uncertain significance (VUS) does not confirm or rule out the diagnosis.

Tumor stains cannot tell inherited disease from a change that happened only in the tumor. GeneReviews states that immunohistochemistry cannot distinguish between tumors caused by FH tumor predisposition syndrome and those caused by biallelic somatic FH variants (changes present in the tumor but not in the person’s germline). Both can look “FH-deficient” under the microscope.

A quiet family history does not settle it. GeneReviews notes that the absence of a known family history does not rule the diagnosis out, because a variant can be new (de novo), signs can vary from person to person, and some relatives who carry the variant may never show signs.

So if a kidney tumor or a fibroid is called FH-deficient, the honest next sentence is: this is a reason to talk about genetic counseling and FH testing, not a final answer by itself.

Why the finding still matters

Even though stains are not a diagnosis, they are a strong prompt to look further.

GeneReviews says that atypical histology and uterine fibroids that show loss of FH staining and positive 2SC staining should prompt germline FH molecular testing. The same staining pattern is often seen in FH-related kidney cancer, and GeneReviews says the condition should also be investigated in anyone with tumors that have its characteristic features. That makes a conversation about germline testing especially important if other personal or family features of HLRCC are present — skin leiomyomas, early or numerous fibroids, or kidney cancer.

If testing finds a pathogenic or likely pathogenic germline FH variant, that result can help the whole family. Our post on family (cascade) testing explains how relatives can be tested for the family’s known variant. For people who carry the variant, regular kidney imaging is the cornerstone of surveillance; see Your Yearly Kidney MRI.

Questions worth taking to your care team

You do not have to become a pathologist. A few practical steps help:

  • Ask for a copy of the full pathology report, including any stain results (FH and 2SC) and any tumor genetic testing already done.
  • Ask whether germline FH testing has been offered, and whether a referral to a genetic counselor is appropriate. Our Genetic Testing page walks through how testing works.
  • Share skin, fibroid and family history, even if it seems unrelated to a kidney or uterine report.
  • Find experience. Our HLRCC Specialists Map lists clinicians familiar with this condition, and the free HLRCC Handbook is written to take with you to appointments.

If you already know you have HLRCC and a new report is labeled FH-deficient, bring it to the team that follows you.

Join us

You do not have to sort a confusing report alone. Connect with families in our Facebook group, Knowledge Saves, and read the HLRCC Handbook. If you’d like to help more people get clear answers, please consider a gift at hlrcc.org/donate-now.

Sources

  1. Kamihara J, Schultz KA, Rana HQ. FH Tumor Predisposition Syndrome. In: Adam MP, et al., eds. GeneReviews®. University of Washington, Seattle; 2006, comprehensive update May 8, 2025. https://www.ncbi.nlm.nih.gov/books/NBK1252/
  2. National Cancer Institute. Hereditary Leiomyomatosis and Renal Cell Cancer (PDQ®)–Health Professional Version. Updated November 6, 2024. cancer.gov/publications/pdq/information-summaries/genetics/hlrcc-syndrome-hp-pdq
  3. Menko FH, Maher ER, Schmidt LS, et al. Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment. Fam Cancer. 2014;13(4):637–644. Free full text

Leave a Reply

Your email address will not be published. Required fields are marked *

This is a staging enviroment